CMS @ 招商證券國際

Monday, August 27, 2018

Company Report

China Merchants Securities (HK) Co., Ltd. Hong Kong Equity Research

CR Pharmaceutical (3320 HK)

Margin expansion made the day

■ 1H18 adj. NP grew 21%, better than expected; on the positive note, Co. delivered strong margin expansion in distribution thanks to the c.20% growth in direct sales; on the negative side, the overall distribution revenue growth was relatively weak due to the sequence of two invoices (hitting GD in 2Q), the interest charges and gearing were also higher than expected

Maintain BUY as the stock is under-valued (below 1x PEG) with decent earnings growth prospect over 2018-19E (19% CAGR of EPS in HK\$)

Pharma mfg and dist. margins were the main positives

1H18 HK\$ denominated rev./adj. NP grew 13%/21%. This was driven by strong distribution GPM expansion (up 1pp to 7.4%, which in turn was driven by c.20% growth in direct sales), and good mfg rev growth (up 15%-16 in RMB ex. invoicing method changes). Worth noting Sanjiu's TCMG sales growth also reaccelerated to c.25% (in RMB terms). Meanwhile, its OTC portfolio continued to optimize after the acquisition of Jiangzhong Pharma, which should contribute c.1% EPS in 2019E.

Ejiao, dist. revenue growth and interest expenses were the main negatives

Ejiao showed flat sales and falling net profit in 1H18. Still mgmt. reassured on the 2H turnaround, citing the accelerating volume growth and manageable inventory. Distribution revenue growth also weakened (up only 1% in RMB) largely reflecting the sequence of two invoices (which hit GD in 2Q). The interest charges and gearing were also greater than expected.

SOTP-based TP upgraded at HK\$14.3 (18x 2019E PER)

We slightly increased 2019 EPS by 2%, reflecting the better-thanexpected gross margin expansion. Our TP was upgraded to HK\$14.3 (from HK\$12.3) mainly as we rolled over to use 2019 EV/NOPAT multiples (instead of 2018).

Financials

HKD mn					2019E
Revenue	146,568	156,705	172,532	189,320	207,052
Growth (%)	8.0%	6.9%	10.1%	9.7%	9.4%
Reported net profit	2,850	2,821	3,483	4,047	4,915
Growth (%)	7.7%	-1.0%	23.4%	16.2%	21.5%
Diluted EPS (HK\$)	0.24	0.50	0.55	0.64	0.78
DPS (HK\$)	0.00	0.09	0.11	0.13	0.16
P/E (X)	49.5	23.8	21.7	18.7	15.4
P/B (X)	2.5	2.0	1.8	1.7	1.5
ROE (%)	13.3%	9.4%	8.8%	9.3%	10.4%

Sources: Company data, CMS (HK) estimates

Su Zhang	Hayden Zhang, CFA
+852 3189 6357	+852 3189 6354
suzhang@cmschina.com.hk	haydenzheng@cmschina.com.hk


WHAT'S NEW

TP slightly upgraded

BUY

Previous	BUY
Price	HK\$11.96
12-month Target Price (Potential upside)	HK\$14.3 (+20%)
Previous	HK\$12.3







%	1m	6m	12m	_
3320 HK	2.5	9.2	22.3	_
HSI	(3.5)	(11.5)	0.6	_

Sector: Pharmaceutical & Healthcare	
Hang Seng Index	28271
HSCEI	10780
Key Data	
52-week range (HK\$)	9.11-12.8
Market cap (HK\$ mn)	75163
Avg. daily volume (mn)	5.82
BVPS (HK\$)	6.66
Shareholding Structure	
China Resources National Corporation	53.0%
Beijing Pharmaceutical Investment Ltd	17.7%
Hengjian Intl Investment	4.6%

Free float 34.5%


Related Research

- 1. CR Pharm (3320 HK) In line delivery (BUY), 2018/03/23
- 2. China Pharmaceutical & Healthcare CMS China healthcare
- sector outlook 2018 (OVERWEIGHT), 2018/01/05 3. CR Pharm (3320 HK) – NDR takeaways: more flavours on market share and KPI (BUY), 2017/09/21
- 4. CR Pharm (3320 HK) Mixed 1H results. Still a good play on the reform themes BUY, 2017/08/28
- CR Pharm (3320 HK) Quality A-share pharma proxy now; more catalysts on its own later, 2017/06/12
- 6. CR Pharm (3320 HK) All eyes on M&A execution (BUY), 2017/03/21
- CR Pharm (3320 HK) Pharmaceutical behemoth to ride on industry secular growth (BUY), 2016/12/14




Monday, August 27, 2018

Focus charts





Sources: Frost & Sullivan Report, CMS (HK)

Figure 3: Segment results breakdown




Sources: Company, CMS (HK) estimates






Sources: Company, CMS (HK) estimates

Figure 4: Net debt and net gearing





Sources: Bloomberg, CMS (HK) estimates



Figure 7: Old vs New

		2018E			2019E	
HKD\$ mn	Before	After	% change	Before	After	% change
Total Revenue	193,485	189,320	-2%	213,158	207,052	-3%
Cost of sales	(160,592)	(154,296)	-4%	(176,282)	(167,712)	-5%
Gross profit	32,892	35,024	6%	36,876	39,340	7%
SG&A expenses	(21,090)	(22,624)	7%	(23,447)	(24,432)	4%
Selling costs	(16,446)	(17,985)	9%	(18,332)	(19,463)	6%
General and Admin expenses	(4,644)	(4,638)	0%	(5,116)	(4,969)	-3%
R&D Expenses	(967)	(947)	-2%	(1,066)	(1,035)	-3%
Operating income/loss	12,342	12,240	-1%	14,102	14,533	3%
Profit from JV&Asso.	218	218	0%	247	247	0%
Other income (net)	1,364	595	-56%	1,560	482	-69%
Finance costs	(2,444)	(2,416)	-1%	(2,335)	(2,589)	11%
Profit Before Taxes	9,973	9,851	-1%	11,835	11,965	1%
Income Tax	(2,094)	(2,069)	-1%	(2,485)	(2,513)	1%
Tax Rate	21%	21%	0%	21%	21%	0%
Minority interest	(3,782)	(3,736)	-1%	(4,488)	(4,537)	1%
Net Income (Reported)	4,097	4,047	-1%	4,862	4,915	1%
Net Income (Adjusted)	4,021	4,020	0%	4,794	4,895	2%
Basic EPS (HK\$)	0.65	0.64	-1%	0.77	0.78	1%
Diluted EPS (HK\$)	0.64	0.64	0%	0.76	0.78	2%
Basic Weighted Average Shares	6,284,506	6,284,506	0%	6,284,506	6,284,506	0%
Diluted Weighted Average Shares	6,284,506	6,284,506	0%	6,284,506	6,284,506	0%
Margins			р.р.			р.р
Gross margin	17.0%	18.5%	1.5%	17.3%	19.0%	1.7%
SG&A	10.9%	12.0%	1.1%	11.0%	11.8%	0.8%
R&D	2.4%	2.5%	0.1%	2.4%	2.4%	0.0%
Operating margin	6.4%	6.5%	0.1%	6.6%	7.0%	0.4%
Profit before tax margin	5.2%	5.2%	0.0%	5.6%	5.8%	0.2%
Minority interest as % of PBT	37.9%	37.9%	0.0%	37.9%	37.9%	0.0%
Net margin	2.1%	2.1%	0.0%	2.3%	2.4%	0.1%
YOY%						
Total Revenue	12%	10%	-2%	10%	9%	-1%
Gross profit	16%	24%	8%	12%	12%	0%
Operating income/loss	16%	15%	-1%	19%	21%	3%
-	1	4.00/			040/	
Net Income	18%	16%	-1%	19%	21%	3%

Sources: Company, CMS (HK)

Valuation

Figure 8: SOTP valuation – 0	CMS methodology			
(HK\$ mn)	2017	2018E	2019E	
NOPAT				
Pharma manufacturing	4,982	5,310	6,022	
Pharma distribution & retail	3,492	4,360	5,459	
Valuation	Multiples		(HK\$ mn)	(HK\$)
Pharma manufacturing	15x NOPAT		90,331	14.4
Pharma distribution & retail	14x NOPAT		76,428	12.2
Net debt at end 2018			(29,865)	(4.8)
Financial assets at end 2018			2,085	0.3
Less: Minorities valuation	15x NOPAT		(48,973)	(7.8)
Equity value at end 2018			90,006	
# of shares (m)			6,285	
ТР				14.3

Sources: Company, CMS (HK)

icker	Name	Last	Mkt Cap	Rating	TP	Upside	Р	/E Ratio		P/	B Ratio		Div Yld		ROE		EV/EBITDA Ratio		
icker	Name	Price	(USD mn)	Rating	IP	(%)	17A	18E	19E	17A	18E	19E	18E	17A	18E	19E	17A	18E	19
D	Distribution and promotio	n																	
1099 HK S	SINOPHARM-H	36.8	12,972				14.7	16.2	14.4	2.2	2.2	2.0	1.9	15.8	14.5	14.9	7.8	8.0	7.0
2607 HK S	Shanghai Pharm-h	20.3	8,347	BUY	28.1	39%	14.4	12.9	10.3	0.8	0.7	0.6	2.5	8.9	8.4	11.2	9.7	9.8	8.3
3320 НК С	CHINA RESOURCES	12.0	9,575	BUY	14.3	20%	21.7	18.7	15.2	1.8	1.7	1.2	1.2	8.8	9.3	8.2	8.6	8.3	7.4
867 HK 0	CHINA MEDICAL SY	14.3	4,531				22.5	15.9	13.5	5.2	3.5	3.0	2.2	24.8	24.3	24.0	20.6	13.0	11.1
1345 HK F	PIONEER PHARM	2.0	332				9.1	N.A.	N.A.	2.3	N.A.	N.A.	N.A.	24.8	N.A.	N.A.	7.6	N.A.	N./

Sources: Bloomberg (estimates as of Aug 27), CMS (HK) estimates * For 2607 HK and 3320 HK we use CMS (HK) Rating/TP/Estimates

Ticker	Name	فيديد	Last	Mkt Cap	F	/E Ratio		P/	B Ratio		Div Yield		ROE		EV/E	BITDA Rat	io
ncker	Name	中文名	Price	(USD mn)	17A	18E	19E	17A	18E	19E	18E	17A	18E	19E	16A	17E	18E
	Distribution and promotion																
501607 CH		上海医药	21.2	8,347	13.4	14.8	13.0	1.4	1.5	1.4	2.0	10.7	10.5	10.7	9.7	9.7	8.2
500998 CH	JOINTOWN PHARM-A	上// 运约 九州通	15.2	4.187	21.8	20.5	16.2	2.4	1.5	1.4	0.8	10.7	7.8	9.0	17.8	12.8	10.3
500998 CH	CHINA MEHECO C-A	· 1. 川通 中国医药	13.2	2,698	21.8	20.5	9.3	3.4	2.0	1.5	1.7	12.2	7.8 17.5	9.0 18.2	17.8	12.0 N.A.	10.5 N.A
000038 CH				2,098	12.9	11.5	9.5 14.7	5.4 1.5	1.9	1.7	0.9	17.7	17.5	10.2	12.4	9.8	N.A 8.2
500511 CH	CHINA NATIONAL-A	国药一致	47.5 26.0	2,811	12.9	16.9 N.A.	14.7 N.A.	2.6	2.1	1.7	0.9	16.3	11.5	11.7	10.5	9.8 N.A.	8.2 N.A
		国药股份		7-													
02589 CH		瑞康医药	12.3	2,711	20.1	14.0	11.0	2.6	2.0	1.7	0.1	13.7	13.9	15.0	12.2	9.3	7.4
503883 CH	LAOBAIXING PHA-A	老百姓	68.2	2,849	45.6	41.6	32.9	6.1	5.5	4.5	0.4	15.5	13.6	14.4	31.1	N.A.	N.A
503939 CH	YIFENG PHARMA-A	益丰药房	58.1	3,090	52.6	49.8	37.8	5.2	5.9	5.3	0.6	10.2	12.0	14.2	37.1	N.A.	N.A
500090 CH	XIN JIANG READ-A	同济堂	5.6	1,174	22.1	N.A.	N.A.	2.0	N.A.	N.A.	N.A.	9.1	N.A.	N.A.	12.3	N.A.	N.A
002727 CH	YUNNAN HONGXIA-A	一心堂	27.2	2,267	25.2	28.3	23.1	3.1	3.7	3.3	1.1	13.7	13.3	14.6	17.5	N.A.	N.A
603368 CH	GUANGXI LIUZHO-A	柳药股份	32.7	1,245	22.1	16.5	13.2	2.5	2.1	1.8	1.4	12.0	13.0	14.0	15.7	N.A.	N.A
503108 CH	SHANGHAI RUNDA-A	润达医疗	10.4	881	32.2	18.2	13.7	3.1	2.3	2.0	1.6	10.0	13.2	15.4	15.7	N.A.	N.A
002462 CH	CACHET PHARMAC-A	嘉事堂	18.6	684	24.8	13.8	11.3	3.0	1.9	1.6	1.7	12.6	12.3	13.1	12.7	8.1	7.2
500713 CH	NANJING PHARMA-A	南京医药	4.8	728	23.3	N.A.	N.A.	2.0	N.A.	N.A.	N.A.	8.9	N.A.	N.A.	13.8	N.A.	N.A
002788 CH	LUYAN PHARMA C-A	鹭燕医药	14.7	415	29.1	N.A.	N.A.	2.6	N.A.	N.A.	N.A.	9.2	N.A.	N.A.	18.8	N.A.	N.A
503716 CH	WUHAN THALYS M-A	塞力斯	16.7	503	37.5	22.0	15.8	3.8	2.6	2.2	0.2	10.6	12.7	15.4	19.2	N.A.	N.A
000705 CH	ZHEJIANG ZHEN-A	浙江震元	6.7	326	45.7	N.A.	N.A.	2.0	N.A.	N.A.	N.A.	4.6	N.A.	N.A.	22.1	N.A.	N.A
	Distribution and promotion av	07300		2.226	24.1	22.3	18.0	2.8	2.6	2.3	1.1	12.5	12.1	12.9	16.3	10.3	8.5

Sources: Bloomberg (estimates as of Aug 27)

Financial Summary

Balance Sheet					
HKD million	2015A	2016A	2017A	2018E	2019E
Cash and ST investments	14,620	16,635	16,729	5,077	10,494
Short Term Receivables	47,514	54,337	67,128	74,519	78,655
Inventories	15,252	18,859	21,406	24,687	25,157
Other current assets	11,471	3,971	6,789	18,789	18,789
Total Current Assets	88,857	93,802	112,052	123,073	133,095
Property. Plant & Equipment	12,578	12,500	14,738	15,475	16,149
Goodwill	16,395	17,405	20,545	20,545	20,545
Deferred tax assets	423	448	574	574	574
Other assets	8,896	9,830	11,700	11,397	11,094
Total Non-current Asset	38,292	40,183	47,556	47,990	48,361
Total Assets	127,149	133,986	160,754	171,063	181,456
Trade and other payables	41,953	50,961	56,496	59,432	63,356
Bank and other loans	24,335	13,737	31,159	31,499	29,499
Current taxation	656	525	560	560	560
Other Current Liabilities	5,279	172	1,248	1,248	1,248
Total Current Liabilities	72,224	70,985	91,734	95,071	96,995
Long term debt	12,883	6,385	3,444	3,444	3,444
Deferred taxes	862	938	964	964	964
Others	1,334	1,376	1,475	1,475	1,475
Total Non-current Liabilities	15,079	8,699	5,883	5,883	5,883
Total Liabilities	87,303	79,684	97,617	100,953	102,877
Minority interest	17,343	16,682	21,267	25,003	29,540
Common equity	22,502	37,620	41,870	45,107	49,039
Total Equity	39,846	54,302	63,137	70,110	78,579
Total Equity & liabilities	127,149	133,985	160,754	171,064	181,456

Cash Flow Statement

HKD million	2015A	2016A	2017E	2018E	2019E
PBT	8,050	8,043	8,582	9,851	11,965
Operating profit before change in WC	9,958	10,453	11,984	13,833	16,182
Change in working capital	(2,213)	(4,153)	(5,411)	(7,736)	(681)
Tax paid	(1,756)	(2,179)	(1,716)	(2,069)	(2,513)
Cash from operating activities	5,989	4,120	4,858	4,028	12,989
Capital expenditure	(2,218)	(1,982)	(2,006)	(2,000)	(2,000)
Others	(1,702)	29	(6,506)	(11,745)	25
Cash from Investing Activities	(3,919)	(1,953)	(8,511)	(13,745)	(1,975)
Long term borrowings	2,110	(11,607)	16,447	400	(2,000)
Reduction In Long Term Debt	623	2,339	(5,283)	0	0
Inc(Dec) In Short Term Borrowings	0	14,767	0	0	0
Net Proceeds From Issue of shares	(1,963)	(1,705)	(2,231)	(2,671)	(2,613)
Others	(2,324)	(4,421)	(5,557)	(809)	(983)
Cash from Financing Activities	(1,554)	(625)	3,376	(3,080)	(5,596)
Net Change in Cash	(521)	758	202	(12,797)	5,417
Net Cash - Beginning Balance	13,736	13,215	13,973	14,162	1,364
Net Cash - Ending Balance	13,215	13,973	14,162	1,364	6,781

Sources: Company, CMS (HK) estimates

Profit & Loss Statement

HKD million	2015A	2016A	2017A	2018E	2019E
Revenue	146,568	156,705	172,532	189,320	207,052
Cost of sales	(123,369)	(132,596	(144,256)	(154,296	(167,712)
Gross profit	23,199	24,109	28,276	35,024	39,340
Selling expenses	(10,112)	(10,947)	(13,869)	(17,985)	(19,463)
Administrative expenses	(3,845)	(3,882)	(4,247)	(4,638)	(4,969)
R&D expense	(709)	(726)	(858)	(947)	(1,035)
Operating profit	8,708	9,394	10,592	12,240	14,533
Profit from JV&Asso.	58	48	141	218	247
Financial cost, net	(2,389)	(1,701)	(2,021)	(2,416)	(2,589)
Other incomes and expenses	1,847	1,213	1,161	595	434
PBT	8,050	8,043	8,582	9,851	11,965
Income tax	(1,968)	(2,075)	(1,716)	(2,069)	(2,513)
Minority interest	(3,232)	(3,147)	(3,384)	(3,736)	(4,537)
Net Profit	2,850	2,821	3,483	4,047	4,915
Adj. Net Profit	1,119	2,472	3,471	4,020	4,895
EPS (HKD) - Basic	0.24	0.50	0.55	0.64	0.78
Adj. EPS (HKD) - Diluted	0.24	0.50	0.55	0.64	0.78
DPS (HKD)	0.000	0.090	0.110	0.128	0.156
Dividend yield	0.0%	1.0%	1.3%	1.5%	1.8%

Ratio

	2015A	2016A	2017A	2018E	2019E
Growth (YoY)					
Revenue	8.0%	6.9%	10.1%	9.7%	9.4%
Gross profit	8.0%	3.9%	17.3%	23.9%	12.3%
Operating profit	3.7%	7.9%	12.8%	15.6%	18.7%
Net profit	7.7%	-1.0%	23.4%	16.2%	21.5%
Adj. net profit	-46.7%	120.8%	40.4%	15.8%	21.8%
Diluted EPS	-46.7%	108.1%	9.8%	15.8%	21.8%

Margin					
Gross Margin	15.8%	15.4%	16.4%	18.5%	19.0%
Operating Margin	5.9%	6.0%	6.1%	6.5%	7.0%
Net Profit Margin	1.9%	1.8%	2.0%	2.1%	2.4%

45.8	46.9	54.2	54.5	54.2
97.6	104.2	142.0	136.5	135.0
95.4	98.1	104.9	101.1	102.2
1.2	1.3	1.2	1.3	1.4
0.9	1.1	1.0	0.9	1.0
58.4%	21.6%	36.0%	51.2%	36.3%
4.9%	4.6%	4.7%	4.7%	5.4%
13.3%	9.4%	8.8%	9.3%	10.4%
	97.6 95.4 1.2 0.9 58.4% 4.9%	97.6 104.2 95.4 98.1 1.2 1.3 0.9 1.1 58.4% 21.6% 4.9% 4.6%	97.6 104.2 142.0 95.4 98.1 104.9 1.2 1.3 1.2 0.9 1.1 1.0 58.4% 21.6% 36.0% 4.9% 4.6% 4.7%	97.6 104.2 142.0 136.5 95.4 98.1 104.9 101.1 1.2 1.3 1.2 1.3 0.9 1.1 1.0 0.9 58.4% 21.6% 36.0% 51.2% 4.9% 4.6% 4.7% 4.7%

Investment Ratings

Industry Rating	Definition
OVERWEIGHT	Expect sector to outperform the market over the next 12 months
NEUTRAL	Expect sector to perform in-line with the market over the next 12 months
UNDERWEIGHT	Expect sector to underperform the market over the next 12 months

Company Rating	Definition
BUY	Expect stock to generate 10%+ return over the next 12 months
NEUTRAL	Expect stock to generate +10% to -10% over the next 12 months
SELL	Expect stock to generate loss of 10%+ over the next 12 months

Analyst Disclosure

The analysts primarily responsible for the preparation of all or part of the research report contained herein hereby certify that: (i) the views expressed in this research report accurately reflect the personal views of each such analyst about the subject securities and issuers; and (ii) no part of the analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.

Regulatory Disclosure

Please refer to the important disclosures on our website http://www.newone.com.hk/cmshk/en/disclosure.html or http://www.cmschina.com.hk/Research/Disclosure.

Disclaimer

This document is prepared by China Merchants Securities (HK) Co., Limited ("CMS HK"). CMS HK is a licensed corporation to carry on Type 1 (dealing in securities), Type 2 (dealing in futures), Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571). This document is for information purpose only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer or solicitation of an offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever to buy or sell any security, financial instrument or any investment or other specific product. The securities, instruments or strategies discussed in this document may not be suitable for all investors, and certain investors may not be eligible to participate in some or all of them. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. CMS HK is not registered as a broker-dealer in the United States and its products and services are not available to U.S. persons except as permitted under SEC Rule 15a-6.

The information and opinions, and associated estimates and forecasts, contained herein have been obtained from or are based on sources believed to be reliable. CMS HK, its holding or affiliated companies, or any of its or their directors, officers or employees ("CMS Group") do not represent or warrant, expressly or impliedly, that it is accurate, correct or complete and it should not be reliad upon. CMS Group will not accept any responsibility or liability whatsoever for any use of or reliance upon this document or any of the content thereof. The contents and information in this document are only current as of the date of their publication and will be subject to change without prior notice. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realized. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business divisions or other members of CMS Group as a result of using different assumptions and/or criteria.

This document has been prepared without regard to the individual financial circumstances and investment objectives of the persons who receive it. Use of any information herein shall be at the sole discretion and risk of the user. Investors are advised to independently evaluate particular investments and strategies, take financial and/or tax advice as to the implications (including tax) of investing in any of the securities or products mentioned in this document, and make their own investment decisions without relying on this publication.

CMS Group may have a long or short position, make markets, act as principal or agent, or engage in transactions in securities of companies referred to in this document and may also perform or seek to perform investment banking services or provide advisory or other services for those companies. This document is for the use of intended recipients only and this document may not be reproduced, distributed or published in whole or in part for any purpose without the prior consent of CMS Group. CMS Group will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this document. This document is for distribution only under such circumstances as may be permitted by applicable law. This document is not directed at you if CMS Group is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. In particular, this document is only made available to certain US persons to whom CMS Group is permitted to make available according to US securities laws, but cannot otherwise be made available, distributed or transmitted, whether directly or indirectly, into the US or to any US person. This document, excluding Hong Kong, Macau and Taiwan).



Important Disclosures for UK Persons

IN THE UNITED KINGDOM, THIS DOCUMENT IS FOR DISTRIBUTION ONLY TO PERSONS WHO: (I) ARE PERSONS FALLING WITHIN THE DEFINITION OF "INVESTMENT PROFESSIONALS" PURSUANT TO ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED, THE "FINANCIAL PROMOTION ORDER"); (II) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) ("HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC") OF THE FINANCIAL PROMOTION ORDER; OR (III) ARE PERSONS TO WHOM AN INVITATION OR INDUCEMENT TO ENGAGE IN INVESTMENT ACTIVITY (WITHIN THE MEANING OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000) MAY OTHERWISE LAWFULLY BE COMMUNICATED OR CAUSED TO BE COMMUNICATED (ALL SUCH PERSONS TO GETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT IS DIRECTED ONLY AT RELEVANT PERSONS AND MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS.

FOR NON-INDEPENDENT RESEARCH COMMISSIONED OR PRODUCED BY PERSONS AUTHORISED IN THE UK BY THE FSA: THIS DOCUMENT DOES NOT PROVIDE AN IMPARTIAL OR OBJECTIVE ASSESSMENT OF THE SUBJECT MATTER AND DOES NOT CONSTITUTE INDEPENDENT "INVESTMENT RESEARCH" UNDER THE APPLICABLE RULES OF THE FINANCIAL SERVICES AUTHORITY IN THE UK. CONSEQUENTLY, THIS DOCUMENT HAS NOT BEEN PREPARED IN ACCORDANCE WITH LEGAL REQUIREMENTS DESIGNED TO PROMOTE THE INDEPENDENCE OF INVESTMENT RESEARCH AND IS NOT SUBJECT TO ANY PROHIBITION ON DEALING AHEAD OF THE DISSEMINATION OF INVESTMENT RESEARCH.

Hong Kong China Merchants Securities (HK) Co., Ltd. Address: 48/F, One Exchange Square, Central, Hong Kong Tel: +852 3189 6888 Fax: +852 3101 0828